Table 2 Patient characteristics of SARS-CoV-2-infected patients randomized to early (≤ 7 days) or late (≥ 10 days) tracheotomy (per protocol population) in the TTCOV19 study
Total | Early tracheotomy | Late tracheotomy | p-value | |
|---|---|---|---|---|
(n = 61) | (n = 27) | (n = 34) | ||
Age, years | 63.5 (11.9) | 61.7 (14.7) | 65.0 (9.0) | 0.29 |
64 (58; 74) | 62 (52; 75) | 65.5 (59; 73) | ||
n = 61 | n = 27 | n = 34 | ||
Male sex | 46 (75.4%) | 20 (74.1%) | 26 (76.5%) | |
Female sex | 15 (24.6%) | 7 (25.9%) | 8 (23.5%) | 1.0 |
Body-mass index, kg/m2 | 36.6 (29.6) | 33.4 (8.3) | 39.0 (38.4) | 0.61 |
32.7 (28.1;35.6) | 33.5 (28.4;35.7) | 30.8 (27.1;35.5) | ||
n = 59 | n = 25 | n = 34 | ||
SAPS3* | 50.6 (7.4) | 51.2 (9.6) | 50.2 (5.3) | 0.63 |
50 (46;54.5) | 50.5 (45;58) | 50 (47; 53) | ||
n = 60 | n = 26 | n = 34 | ||
Covid-19 medication | ||||
No | 53 (88.3%) | 25 (92.6%) | 28 (84.8%) | |
Remdesivir | 7 (11.7%) | 2 (7.4%) | 5 (15.2%) | 0.35 |
Tocilizumab | 0 (0%) | 0 (0%) | 0 (0%) | |
Coexisting illness | ||||
Heart disease† | 12 (19.7%) | 4 (14.8%) | 8 (23.5%) | 0.60 |
Hypertension | 35 (57.4%) | 15 (55.6%) | 20 (58.8%) | 1.00 |
Asthma | 8 (13.1%) | 4 (14.8%) | 4 (11.8%) | 1.00 |
Chronic obstructive pulmonary disease | 1 (1.6%) | 0 (0.0%) | 1 (2.9%) | 1.00 |
Obstructive sleep apnoea syndrome | 9 (14.8%) | 4 (14.8%) | 5 (14.7%) | 1.00 |
Diabetes | 17 (27.9%) | 8 (29.6%) | 9 (26.5%) | 1.00 |